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Background—Chlamydia pneumoniae (Cp) has been demonstrated in arteries and abdominal aortic aneurysms (AAAs).
However, the validity of the methods used is questioned, and antibiotic treatment trials have thus far shown
disappointing results. Nevertheless, antibodies against the Cp outer membrane proteins (OMPs) have been associated
with progression of atherosclerosis and AAAs. The aim of this study was to detect Cp OMPs in the wall of AAA patients
by use of purified serum antibodies directed against Cp OMP and to assess potential cross-reacting proteins in AAA
walls.
Methods and Results—Seventeen patients undergoing infrarenal AAA repair were studied. Full AAA thickness tissue was
collected from the anterior wall of the aneurysm. Anti-OMP was extracted from seropositive AAA patients by use of
an ELISA kit (Labsystems). Analysis was performed by use of 2D polyacrylamide gel electrophoresis, immunoblotting,
and mass spectrometric protein identification. OMP antigens were not detected in 16 of 17 AAA walls. However, 3
major AAA proteins cross-reacted with anti-OMP. The proteins were all identified as heavy chains of human
immunoglobulin.
Conclusions—We could not find evidence of Cp OMP in 16 of 17 AAA walls, but instead, all samples showed a strong
cross-reaction between Cp OMP antibodies and human immunoglobulin. This might indicate that AAA is an
autoimmune disease, perhaps triggered by an initial Cp infection. (Circulation. 2004;109:2097-2102.)
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Antibodies against Chlamydia pneumoniae (Cp) havebeen associated with atherosclerosis, acute myocardial
infarction, and expansion of abdominal aortic aneurysms
(AAAs).1–8 Furthermore, Cp has been demonstrated in AAAs
and in atherosclerotic lesions of coronary, carotid, and fem-
oral arteries by a variety of tests, including immunohisto-
chemical techniques, ELISA, the polymerase chain reaction
(PCR), electron microscopy, and isolation in tissue cul-
ture.9–15 However, detection rates of Cp in atherosclerotic
lesions by PCR vary between 0% and 100%,16 and the
correlation between demonstration of Cp DNA or antigen in
tissue from aneurysms or plaque material and the antibody
titers in serum is not convincing.17,18 Furthermore, we have
recently shown that there was no clear evidence of the
presence of outer membrane protein (OMP) in the wall of
AAAs but a likely cross-reaction between rabbit anti-OMP
and hemoglobin.19 Finally, intervention trials with macrolides
seem to have only a transient effect, if any.20
Consequently, the relationship between Cp, AAAs, and
atherosclerotic disease remains unknown, and the clinical
impact of detecting the organism is unresolved. However, we
have demonstrated in prospective studies that antibodies
against Cp are associated with the progression of AAAs and
lower-limb atherosclerosis.1,8,21,22 An explanation could be
that pathogenetically important antibodies cross-react with
Cp OMP. The aim of the present study was to detect OMP in
AAA wall tissue by use of purified Cp OMP antibodies from
AAA patients and to search for potential cross-reacting
proteins in the wall of AAAs.
Methods
Isolation of Specific Antibodies Against the OMP
of Cp From Patient Sera
Sera were taken from 5 patients with an AAA, an IgA titer 64, and
an IgG titer128. The patients had taken part in one of our previous
studies on the correlation between the progression of lower-limb
atherosclerosis, the natural history of AAAs, and antibodies against
Cp.1,8 The sera were applied to a new commercially available ELISA
test from Labsystems (LOY-EIA). The LOY-EIAs for Cp IgG and
IgA are indirect solid-phase enzyme immunoassays with Cp OMP as
immobilized antigen.22 Isolation and purification of specific antibod-
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ies against Cp OMP were as follows: 100 L of serum sample was
diluted 1:2 in PBS buffer (in mmol/L: 2.7 KCl, 1.8 KH2PO4, 10.1
Na2HPO4, 140 NaCl, pH 7.4) and added to the wells coated with Cp
OMP. The plates were incubated at 37°C for 1 hour under gentle
shaking and washed 10 times with PBS. The purified antibodies were
eluted by addition of 100 L elution buffer (0.1 mol/L glycine, pH
3.0) to each well. The eluates were collected and quickly neutralized
to pH 7.4 with 1 mol/L Trizma base, pH 9.0.
AAA Samples
AAA wall samples were studied in 17 male patients undergoing
infrarenal AAA repair at the Department of Vascular Surgery,
Viborg Hospital, Denmark. Data on age, smoking, and hypertension
are shown in Table 1. Their mean age was 71.9 years (range, 46 to
85 years). The maximal cross-sectional diameter of the AAA was
measured by ultrasound and/or CT scanning performed immediately
before the operation.
The study was approved by the local scientific ethics committee
and reported to the data protection authorities. All patients gave
informed consent.
Full AAA thickness tissue was harvested in a standardized manner
from the central part of the anterior wall of the aneurysm and stored
immediately at 22°C. Approximately 1 g was rinsed 3 times with
PBS for 10 minutes. The specimens were crushed in 1 mL cold
sucrose buffer (300 mmol/L sucrose, 10 mmol/L Tris, pH 7.4)
containing the protease inhibitors 1 mmol/L Na-EDTA, 1 mmol/L
PMSF, 1 mol/L pepstatin, and 1 mol/L leupeptin with an
Ultra-Turax homogenizer. Cell debris was removed by centrifuga-
tion (14 000g for 20 minutes). Clear protein solutions were used for
subsequent gel electrophoresis.
Gel Electrophoresis and Immunoblotting
The total AAA protein content of each sample was estimated by
Bio-Rad Protein Assay according to the method of Bradford.23 For
1D gels,25 g of prepared sample was loaded in each well and run
on 10% to 20% gradient polyacrylamide minigels (NOVEX). For 2D
gels, the serum was dissolved in lysis buffer. Rehydration buffer was
added, and the first dimension was run with immobilized pH-
gradient (IPG) strips (pH 3 to 10, non-linear) from Amersham
Biosciences. The second dimension was performed on homemade
polyacrylamide gels (12% T, 3% C) that were fixed in 50% (vol/vol)
methanol, 12% (vol/vol) acetic acid, and 0.0185% (vol/vol) formal-
dehyde for at least 1 hour or overnight. They were then washed 3
times for 20 minutes in 35% (vol/vol) ethanol, pretreated for 1
minute in pretreatment solution (0.02% [wt/vol] Na2S2O3 · 5H2O),
and rinsed 2 times for 3 minutes in water. Staining of gels was
performed for 20 minutes in 0.2% (wt/vol) AgNO3, 0.028% (vol/vol)
formaldehyde, after which they were rinsed 2 times for 20 seconds in
water. Development was performed in development solution (6%
[wt/vol] Na2CO3, 0.0185% [vol/vol] formaldehyde, 0.0004% [wt/
vol] Na2S2O3 · 5H2O) for 3 minutes, and was stopped in stop
solution (50% [vol/vol] methanol, 12% [vol/vol] acetic acid). Fi-
nally, the gels were dried between cellophane sheets and sealed in
plastic bags.
From 1D and 2D gels, proteins were transferred to nitrocellulose
membranes that were blocked for 1 hour with 0.5% skim milk and
0.05% Tween-20 in PBS and incubated at room temperature for 1
hour with pure anti-OMP antibody (1:100) isolated from patient sera
as described above. The blots were washed and reacted with
horseradish peroxidase–conjugated secondary antibody (sheep anti-
human antibody from the LOY-EIA ELISA kit) diluted 1:1000. The
bands were visualized by use of an enhanced chemiluminescence kit
and enhanced chemiluminescence hyperfilm (Amersham Pharmacia
Biotech).24
Protein Identification
Protein spots were excised from silver-stained 2D gels and digested
by use of the protocol described by Shevchenko et al.25 Briefly, the
gel spots were washed with 50 mmol/L NH4HCO3/acetonitrile (1:1),
followed by dehydration with acetonitrile. The proteins were reduced
in 10 mmol/L dithiothreitol/50 mmol/L NH4HCO3 for 1 hour at 56°C
and alkylated in 55 mmol/L iodoacetamide/50 mmol/L NH4HCO3 for
2 hours at room temperature. The gel pieces were washed several
times in 50 mmol/L NH4HCO3, followed by dehydration with
acetonitrile. The proteins were digested overnight with trypsin
(Promega, modified trypsin) at 37°C, and the resulting peptide
mixtures were analyzed by tandem mass spectrometry at Alphalyse
A/S (Odense, Denmark). The peptide masses obtained were used to
query the non-redundant sequence database (NRDB) for protein
identification. The NRDB database contains more than 360 000
entries and is maintained and updated by the European Molecular
Biology Laboratory. It was specifically tested whether the proteins
could be fragments of Cp OMP.
Results
Anti-OMP antibodies present in patient sera were isolated by
affinity purification by allowing the antibodies to react with
immobilized Cp-specific OMP. After purification, we
checked that the recovered antibodies still possessed the
OMP reactivity by Western blot analysis of pure recombinant
OMP. As demonstrated in Figure 1 (lane 1), recombinant
major OMP runs in a silver-stained gel as a single band of
40 kDa. Immunoblotting was performed by use of the
affinity-purified anti-OMP antibody (lane 2). A strong signal
was obtained, corresponding to 40 kDa. Two very faint,
higher-molecular-mass bands were also observed on the
TABLE 1. Patient Characteristics
AAA Size, cm
5–6 6
No. 12 5
Age in years, median (range) 71.1 (46–85) 72.7 (69–85)
Current smoking 8 7
Diagnosis of hypertension 4 4
Figure 1. Immunoblot analysis of affinity-purified Cp OMP anti-
body. Lane 1, Pure recombinant OMP was electrophoresed and
silver-stained. Protein is very pure, with only 1 band present at
40 kDa, as expected. Lane 2, Western blot of pure recombi-
nant OMP reacted with affinity-purified anti-OMP antibody,
showing that anti-OMP reacts with OMP antigen.
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Western blot. These may be because of small amounts of
aggregates of the recombinant protein or because of small
amounts of impurities in the protein sample cross-reacting
with the antibody. Immunolabeling controls performed by use
of anti-OMP preabsorbed with the recombinant OMP exhib-
ited no labeling (not shown).
We then investigated whether we could detect the presence
of OMP in the AAA wall from 17 patients by use of the
anti-OMP antibody. Western blots with AAA homogenate
and anti-OMP antibody are shown in Figure 2. No specific
reaction was seen at 40 kDa according to the molecular mass
of OMP. Only patient 13 showed some reactivity at40 kDa
that we cannot completely exclude as being due to the
presence of OMP. However, this is an exception, because
generally a much stronger reaction (also from patient 13) was
seen with cross-reacting proteins 50 kDa from all AAA
patients. In addition, other less strongly reacting bands were
noticed with still slightly higher molecular masses. The
reaction was equally strong irrespective of age, current
smoking, diagnosis of hypertension, and AAA size.
To identify the reacting proteins, we first performed a
high-resolution purification of aortic wall proteins from 1
selected patient (patient 1) by 2D gel electrophoresis. One of
the gels was Western blotted and reacted with the anti-OMP
antibody (Figure 3A), and another gel was silver-stained and
served as reference (Figure 3B). By aligning the blot to the
silver-stained gel, 3 proteins with pI of 10 were cut out
from the silver-stained gel (Figure 3C) to be identified by
sequence determination by use of tandem mass spectrometry.
The mass spectrometry analysis revealed the sequence of
several peptides from each of the 3 proteins cut out. All
peptides were found to be present in the heavy chain of
human immunoglobulin (Table 2). It was specifically ana-
lyzed whether the proteins could originate from the Cp OMP
protein. This was not the case.
Discussion
We isolated and affinity-purified anti-OMP antibody from
sera of patients with AAAs. After verifying that the anti-OMP
antibody had retained its activity for recognizing recombinant
OMP, we used the antibody to analyze the aortic walls of 17
AAA patients by Western blotting. We found a positive
reaction in the samples from all 17 patients. However, OMP
could not be detected in the AAA wall, because no signal was
seen at 40 kDa except in 1 sample (patient 13), in which
several bands from 30 to 100 kDa were reacting, including a
minor band at 40 kDa. However, this reaction is apparently
very unspecific, because a much stronger band is found above
50 kDa. All the other samples also contained a number of
cross-reacting proteins beyond 50 kDa.
Theoretically, these bands could arise from a 40-kDa
protein that is modified, eg, glycosylated, or has reacted with
a component of a matrix protein that adds 10 to 20 kDa to the
protein. However, OMP synthesized in vivo forms large
oligomeric structures stabilized by disulfide bonds,26 but it is
expected to migrate in the monomeric form under electro-
phoresis, because the disulfide bonds will be disrupted by the
addition of the reducing agent dithiothreitol to the samples
before analysis. The monomer could still migrate with a
molecular mass other than 40 kDa if it is modified in vivo by,
eg, glycosylations. However, this does not seem to be the
case, because native OMP, immunoprecipitated from infected
HeLa cells, migrates as an 40-kDa band,27 indicating that
the protein is not substantially modified in HeLa cells. Thus,
it is expected that putative OMP also present in the AAA wall
should migrate as a 40-kDa band.
In summary, to the best of our knowledge, there is no
indication that such modifications take place. Furthermore,
the 2D gel Western blots showed that the cross-reactivity at
50 to 60 kDa was not seen at the expected pI of OMP of6
but instead at a pI of 10. In addition, the cross-reacting
proteins were all identified by mass spectrometry sequencing
as the heavy chain of immunoglobulin. Unfortunately, we did
not have sera from the patients who had undergone surgery.
Thus, the negative result with regard to the presence of OMP
could be because we had examined the AAA walls only from
seronegative patients. This is not very likely, however,
because 62% to 83% of AAA patients are reported to be
seropositive for Cp, depending on the definition.1 The fact
that 16 walls examined showed the same pattern with no
signs of OMP present, and in 1 sample perhaps only very
faint amounts present, makes it very unlikely that we, by
coincidence, examined walls only from seronegative patients.
Figure 2. Western blot analysis of proteins
from AAA wall proteins (lanes 1–17). Blot was
reacted with affinity-purified Cp OMP serum
antibodies. It was not possible to detect OMP
as a 40-kDa protein. However, several cross-
reacting bands were found, especially one at
50 kDa, together with some minor bands with
slightly higher molecular mass.
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The role of Cp remains controversial; we have earlier
failed to demonstrate the presence of Cp in AAA walls by
PCR methods and immunoblotting.19,28 The PCR test is a
diagnostic method for Cp infection, which claims to yield
data of high sensitivity compared with other methods, includ-
ing culturing. However, to validate the PCR technique be-
tween different laboratories, Apfalter16 showed that attempts
to detect intravascular Cp DNA directly varies between 0%
and 100%. One reason for this discrepancy can be contami-
nation of samples, because several laboratories have reported
positive findings in the negative controls. Apparently, immu-
nohistochemistry yields more positive results for Cp than
PCR techniques, and the method also has a poor correlation
with PCR findings.29 However, we have demonstrated by
Western blotting that positive signals might be a result of
cross-reacting proteins.19
In principle, the presence of cross-reacting proteins could
be related to late colonization of the mural thrombus, but we
have not been able to detect either Cp OMPs or Cp DNA in
the mural thrombus.19,28 On the basis of the discrepancy of
results regarding the presence of Cp in AAAs and the
methodological problems in direct detection of the organism,
it may be that Cp is not present in AAA walls at a late stage.
This, however, does not exclude the possibility that it may
have initiated the inflammatory reaction that subsequently
leads to production of cross-reacting antibodies.
Conversely, Tambiah et al30 showed in an animal model
that Cp seems to stimulate the influx of macrophages and
dilatation of the abdominal aorta. We have shown in earlier
studies1,8 that AAA expansion was positively correlated with
the presence of antibodies against Cp. In the present study,
we have shown that these antibodies react with the OMP
protein and, in addition, shown that other proteins, possibly
immunoglobulins, are cross-reacting with the anti-OMP an-
tibody. The correlation between antibodies against Cp and the
progression of small AAAs strongly suggests a pathogenetic
role of the protein that caused the antibodies to be produced.
From this study, we cannot conclude that this protein was
OMP or another protein with epitopes similar to OMP. The
missing presence of OMP suggests that another protein may
be involved. The demonstrated cross-reaction with immuno-
globulins could indicate an autoimmune reaction, because
antibodies reacting on antibodies are known only in autoim-
mune diseases.
This hypothesis is supported by histological examination
of AAA walls, which shows the abundant presence of cells of
chronic inflammation and Russell bodies, as in the autoim-
mune disease Hasimoto’s thyroiditis.31–33 Furthermore, cyto-
kines that modulate the immune response and activate prote-
olysis,34 and substantial increases of IgG compared with
aortic occlusive diseases and normal aortas,32 are found in
AAA walls. An autoimmune reaction could be triggered by
an initial Cp infection, explaining the fact that the antibodies
react with OMP and apparently cross-react with immuno-
globulins. An autoimmune disease instead of an infective
disease would have a dramatic impact on the choice of
potential medical treatment, because antiinflammatory drugs
rather than antibiotics might be effective.
In addition, the observations might indicate that this
cross-reaction is unique for AAAs or a result of coexisting
atherosclerosis, which also has been associated with chla-
mydial infection. Unfortunately, we did not harvest material
from other tissues such as native vessels or occlusive athero-
sclerotic arteries. Future studies are directed toward such
tissues and examining whether rheumatic factors are associ-
ated with AAAs and aneurysmal progression and whether
rheumatic factors cross-react with OMP.
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